Mirum Pharmaceuticals, Inc. has acquired Bluejay Therapeutics for $620,000,000. Bluejay Therapeutics is a biotechnology company focused on developing innovative cures for infectious diseases, with its initial target indication being chronic hepatitis D virus (HDV) infection. Its mission centers on advancing liver science to improve patient lives by creating new therapies for viral hepatitis and other serious liver diseases, where current treatment options are often limited and disease progression can be rapid and life-threatening.
This acquisition significantly strengthens Mirum Pharmaceuticals' strategic position within the rare disease and liver science sector. Mirum Pharmaceuticals is established in developing and bringing to market novel treatments for rare and severe liver diseases. The integration of Bluejay's specialized pipeline and deep scientific expertise is set to expand Mirum's global leadership, particularly within the complex and underserved area of chronic viral hepatitis.
A cornerstone of this acquisition is Bluejay's investigational lead candidate, Brelovitug (BJT-778). This therapy has demonstrated promising efficacy in Phase 2 studies for chronic HDV, achieving notable virologic response rates and combined endpoints. This aligns directly with Mirum's objective to significantly shift the current treatment paradigm for serious liver conditions. The combined entity is poised to effectively leverage Bluejay's scientific insights into infectious diseases and liver pathology, synergizing with Mirum's established development and commercialization capabilities.
This strategic move is expected to accelerate the research and development of new therapeutic options and broaden the availability of treatments for patients suffering from challenging liver diseases, including chronic hepatitis B and D. By uniting their respective strengths and scientific approaches, Mirum and Bluejay aim to deliver advanced, potentially life-changing therapies that address significant unmet medical needs and ultimately enhance patient outcomes globally.